Q32 Bio Inc QTTB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
-
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
-
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
-
Q32 Bio to Participate in Upcoming September Investor Conferences
-
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $7.77
- Day Range
- $7.28–7.82
- 52-Week Range
- $1.91–23.57
- Bid/Ask
- $7.00 / $8.28
- Shares Outstanding
- 29.77M
- Market Cap
- $223.87M
- Volume/Avg
- 678,979 / 770,082
Key Statistics
- Price/Earnings (Normalized)
- 3.32
- Price/Sales
- 2.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 22
- Website
- https://www.q32bio.com
Valuation
|
Metric
|
QTTB
|
|---|---|
Price/Earnings (Normalized) | 3.32 |
Price/Book Value | 1.69 |
Price/Sales | 2.08 |
Price/Cash Flow | — |
Price/Earnings
QTTB
Financial Strength
|
Metric
|
QTTB
|
|---|---|
Quick Ratio | 20.12 |
Current Ratio | 20.30 |
Interest Coverage | — |
Quick Ratio
QTTB
Profitability
|
Metric
|
QTTB
|
|---|---|
Return on Assets (Normalized) | 40.08% |
Return on Equity (Normalized) | 89.49% |
Return on Invested Capital (Normalized) | 62.67% |
Return on Assets
QTTB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!&G#yPX | LOCK|#qBb | $127B | |||
| Moderna Inc
MRNA
| LOCK|!%kW$Ck | LOCK|d$ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|j?dxg@q | LOCK|!S?t | $81B | |||
| argenx SE ADR
ARGX
| LOCK|M&$vRVl | LOCK|m< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|th<MR$! | LOCK|FTg | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|g#MJPr | LOCK|>D&y | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!#lB<$hH | LOCK|<XL!N | $27B | |||
| Incyte Corp
INCY
| LOCK|P%w@t$ | LOCK|f>p | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|w^%szL> | LOCK|J# | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Yk@^Qr? | LOCK|@#J | $14B |
United States